Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sorafenib + metformin in KRAS-mutant advanced non-small cell lung cancer
2011-004683-30Phase 2Active
- Sponsor
- VU University Medical
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib and metformin in non-small cell lung cancer (NSCLC), sponsored by VU University Medical. Primary endpoint: No-progression rate at 6 weeks. Started Mar 2012; status: active.
02
Drugs
sorafenibmetformin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2011-004683-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004683-30.